tirzepatide in singapore Price & Guide Tirzepatide (Mounjaro) medication for weight

Appropriate supportive treatment should be provided according to the patients clinical signs and symptoms

The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, randomly assigned 751 adults with obesity to either tirzepatide or semaglutide for 72 weeks.[1] The results were clear: Average weight loss with tirzepatide: 20.2% Average weight loss with semaglutide: 13.7% Tirzepatide patients were also more likely to hit major milestones 10%, 15%, 20%, and even 25% body weight loss

This increases GI side effects without proportionally increasing weight loss

Tirzepatide is only available as an injectable medication through FDA-approved channels

There are no FDA-approved combinations and no published clinical trials studying this pairing